Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacetuzumab (SGN-40) with R-ICE in Relapsed/Refractory DLBCL
NCT00529503Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Sep 2007
- Primary completion
- Dec 2009
- Countries
- 10
01
Overview
A Phase 2 trial of dacetuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Seagen Inc.. Started Sep 2007; status: terminated.
02
Drugs
dacetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00529503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00529503.